| 0 (0%) | 09-27 09:32 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.53 | 1-year : | 1.88 |
| Resists | First : | 1.31 | Second : | 1.61 |
| Pivot price | 1.29  |
|||
| Supports | First : | 0.83 | Second : | 0.69 |
| MAs | MA(5) : | 1.21 |
MA(20) : | 1.22 |
| MA(100) : | 0.83 |
MA(250) : | 0.85 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 28.5 |
D(3) : | 38 |
| RSI | RSI(14): 46.7 |
|||
| 52-week | High : | 1.61 | Low : | 0.42 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ACRX ] has closed above bottom band by 4.4%. Bollinger Bands are 16.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.18 - 1.18 | 1.18 - 1.19 |
| Low: | 1.06 - 1.07 | 1.07 - 1.08 |
| Close: | 1.11 - 1.12 | 1.12 - 1.14 |
Tue, 09 Jan 2024
AcelRx Announces Rebranding With Name Change to Talphera, Inc. - PR Newswire
Wed, 08 Nov 2023
AcelRx Pharmaceuticals: Q3 Earnings Snapshot - qz.com
Wed, 05 Apr 2023
AcelRx Pharmaceuticals Announces Closing of Divestment of DSUVIA® to Alora Pharmaceuticals - PR Newswire
Tue, 25 Oct 2022
AcelRx Pharmaceuticals Announces Reverse Stock Split - PR Newswire
Wed, 06 Oct 2021
AcelRx Pharmaceuticals (ACRX) CEO Vincent Angotti Details Near Term Revenue Prospects - The Wall Street Transcript
Mon, 02 Aug 2021
User - FinancialContent
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 17 (M) |
| Held by Insiders | 1.203e+007 (%) |
| Held by Institutions | 2.6 (%) |
| Shares Short | 751 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.683e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 828.2 % |
| Return on Equity (ttm) | -32.3 % |
| Qtrly Rev. Growth | 370000 % |
| Gross Profit (p.s.) | -147.89 |
| Sales Per Share | -98.31 |
| EBITDA (p.s.) | -6.42308e+006 |
| Qtrly Earnings Growth | -2.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -19 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 0.54 |
| Dividend | 0 |
| Forward Dividend | 508110 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|